Clinical Research Directory

Cardiac Allograft Vasculopathy Inhibition With Alirocumab

Sponsor: Stanford University

Summary

The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.

Official title: PCSK9 Inhibition After Heart Transplantation

Key Details

Conditions

Interventions

Locations (1)